US Patent

US10137124 — Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

Method of Use · Assigned to Array Biopharma Inc · Expires 2037-10-10 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compounds that inhibit RET kinase and are useful in treating and preventing diseases associated with RET kinase, such as those caused by RET mutations.

USPTO Abstract

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X 1 , X 2 , X 3 , X 4 , Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3450 — Retevmo
U-3450 — Retevmo
U-3450 — Retevmo
U-3450 — Retevmo
U-3450 — Retevmo
U-3450 — Retevmo

Patent Metadata

Patent number
US10137124
Jurisdiction
US
Classification
Method of Use
Expires
2037-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.